newsfilter
← Latest News
GlobeNewswire·

MediWound Reports Second Quarter 2023 Financial Results and Provides Company Update

EscharEx® Phase III study protocol: FDA/EMA-aligned; patient enrollment commencing early 2024; two key research collaborations with wound industry leaders NexoBrid® U.S. commercial launch timing not